TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC
Written by
Cancer Network
Published
0
comments
0
min
Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.